Is XTLB or ZVRA more undervalued in 2026?

CirclFi compares XTL Biopharmaceuticals Ltd. (XTLB) and Zevra Therapeutics, Inc. (ZVRA) using 13 institutional-grade valuation models. XTLB has a Quality of Company score of 1.7/10 while ZVRA scores 6.8/10.

Which is a better buy — XTLB or ZVRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XTLB and ZVRA valuations compare?

XTLB at $2.44 and ZVRA at $11.59 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XTLB vs ZVRA Valuation Comparison 2026 — Intrinsic Value Analysis

XTLB

Pharmaceutical Preparations

XTL Biopharmaceuticals Ltd.

Quality

1.7

out of 10

Value Trap

—

Price

$2.44

Last close

Models

5/13

Active

ZVRA

Pharmaceutical Preparations

Zevra Therapeutics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$11.59

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	XTLB Fair Value	XTLB Upside	ZVRA Fair Value	ZVRA Upside
Bayesian DCF	Intrinsic	$0.75	-69.1%	$7.90	-31.9%
Earnings Power Value	Intrinsic	—	—	$8.07	-30.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$0.72	-71.6%	$30.74	+165.2%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XTLB vs ZVRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XTLB vs ZVRA — Which Stock Is More Undervalued?

ZVRA scores higher with a 6.8/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XTL Biopharmaceuticals Ltd. (XTLB) and Zevra Therapeutics, Inc. (ZVRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XTLB currently trades at $2.44 with a QOC of 1.7/10, while ZVRA trades at $11.59 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).